Regenerex Pharma (RGPX) 10-K 23 Jun 21 2020 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Mar. 31, 2021	Jun. 23, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Period End Date	Mar. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--03-31
Entity File Number	000-53230
Entity Registrant Name	PEPTIDE TECHNOLOGIES, INC.
Entity Central Index Key	0001357878
Entity Tax Identification Number	32-0535345
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5348 Vegas Drive #177
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89108
City Area Code	702
Local Phone Number	805-7525
Title of 12(g) Security	Common Stock, $0.001 par value per share
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float	$ 0
Entity Common Stock, Shares Outstanding		127,112,660

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Current Assets
Cash and cash equivalents	$ 6,902	$ 5,460
Prepaid expenses	1,213
Inventories		246,691
Total Current Assets	8,115	252,151
Website, net of accumulated amortization of $19,645 and $14,984 as of March 31, 2021 and 2020, respectively	2,355	7,016
Total Assets	10,470	259,167
Current Liabilities
Accounts payable	48,038	51,098
Related-party advances	130,992	130,992
Accrued compensation	221,192	221,192
Other accrued liabilities	71,003	45,436
Current portion of notes payable to shareholder	150,094	70,000
Total Current Liabilities	621,319	518,718
Notes Payable to shareholder, net of current portion	224,177	221,723
Total Liabilities	845,496	740,441
Stockholders' Deficit
Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 issued and outstanding as of March 31, 2021 and 2020.	127,113	127,113
Additional paid-in capital	776,963	776,963
Accumulated deficit	(1,739,102)	(1,385,350)
Total Stockholders' Deficit	(835,026)	(481,274)
Total Liabilities and Stockholders' Deficit	$ 10,470	$ 259,167

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Statement of Financial Position [Abstract]
Accumulated Amortization, Website	$ 19,645	$ 14,984
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	675,000,000	675,000,000
Common stock, shares issued	127,112,660	127,112,660
Common stock, shares outstanding	127,112,660	127,112,660

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Sales	$ 1,775	$ 2,608
Cost of Sales
Goods sold	1,129	1,712
Provision for write down of inventory	245,563
Total Cost of Sales	246,692	1,712
Gross Profit (Loss)	(244,917)	896
Operating Expenses
General and administrative	52,543	61,031
Sales and marketing	8,771	16,868
Total Operating Expenses	61,314	77,899
Operating Loss	(306,231)	(77,003)
Other (Expense):
Interest expense	(42,905)	(28,658)
Foreign currency loss	(4,616)	(5,928)
Total Other (Expense)	(47,521)	(34,586)
Net Loss	$ (353,752)	$ (111,589)
Basic and Diluted Loss per Common Share	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding	127,112,660	127,112,660

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash Flows From Operating Activities:
Net loss	$ (353,752)	$ (111,589)
Adjustments to reconcile net loss to cash flows used in operating activities
Provision for write down of inventory	245,563
Depreciation	4,661	6,991
Foreign currency adjustments	4,616	7,632
Changes in operating assets and liabilities:
Inventories	1,128	(246,691)
Prepaid expenses	(1,213)	9,070
Accounts payable and accrued liabilities	36,345	43,408
Net cash used for operating activities	(62,652)	(291,179)
Cash Flows From Investing Activities:
Website development		(6,000)
Net cash used for investing activities		(6,000)
Cash Flows From Financing Activities:
Related-party advances		2
Proceeds from notes payable to shareholder	64,094	214,091
Net cash provided by financing activities	64,094	214,093
(Decrease) Increase in cash and equivalents	1,442	(83,086)
Cash and cash equivalents, beginning of year	5,460	88,546
Cash and cash equivalents, end of year	6,902	5,460
Supplemental Cash Flow Information:
Income taxes
Interest
Non Cash Investing and Financing Activities:
Accrued interest converted into note payable to shareholder	$ 13,838

Statements of Stockholders' Def

Statements of Stockholders' Deficit - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Mar. 31, 2019	$ 127,113	$ 776,963	$ (1,273,761)	$ (369,685)
Balance (in Shares) at Mar. 31, 2019	127,112,660
Net Loss			(111,589)	(111,589)
Balance at Mar. 31, 2020	$ 127,113	776,963	(1,385,350)	$ (481,274)
Balance (in Shares) at Mar. 31, 2020	127,112,660			127,112,660
Net Loss			(353,752)	$ (353,752)
Balance at Mar. 31, 2021	$ 127,113	$ 776,963	$ (1,739,102)	$ (835,026)
Balance (in Shares) at Mar. 31, 2021	127,112,660			127,112,660

Nature Of Operations

Nature Of Operations	12 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature Of Operations	NOTE 1 – NATURE OF OPERATIONS Peptide Technologies, Inc., (the “Company” or “Peptide”), was incorporated in the State of Nevada, United States of America, on November 18, 2005. The Company’s business is to develop and market skincare products. Its plan is to build a state-of-the-art online store with a direct marketing and sales funnel aimed at targeted channels, using internet, social media, and content marketing. The Company’s marketing approach uses vetted channels that encompass several steps to gauge performance data from marketing tests against other campaigns in real-time with the ability to modify content delivery to targeted consumers immediately. The Company will engage a team with proprietary algorithmic software to assist in making these marketing decisions. Management believes this will provide the Company a distinct advantage over other companies that outsource marketing and advertising efforts to third parties. The skincare space is well-suited for direct-to-consumer sales, and there are several channels that the Company will leverage to introduce its unique branding and creative advertising assets. Creating brand visibility, along with the back-end support to process orders, is one of the Company’s key strengths over smaller competitors in the space. In addition, the Company will create a brand that allows visibility and awareness to be molded organically, thereby increasing the brand’s value quickly. The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital to carry out its plan of operation and competition from existing consumer product companies. The majority of manufacturing, distribution, marketing, and sales operations will be outsourced. However, strategic planning and development will be performed internally by the Company. This includes, but is not limited to, developing our catalog of products, developing proprietary skincare formulations, pricing our products, deciding which markets to target, deciding which influencers to engage in marketing campaigns, developing sales channels such as our e-commerce sites, determining which marketing initiatives to pursue, and selecting strategic partners and suppliers to advance our business plan.

Going Concern

Going Concern	12 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $1,739,102 as of March 31, 2021. The Company also has current liabilities in excess of current assets of $613,204. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Basis of Presentation and Use of Estimates These financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could ultimately differ from those estimates. The most significant estimate impacted these financial statements relates to the recovery of our inventories due to the limited shelf life. Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original maturities of three months or less. Inventories Inventories consist of purchased skincare products held for resale.. Inventories are valued at the lower of cost and net realizable value with the cost being determined on a first-in, first-out basis (FIFO) cost method. During the year ended March 31, 2021, the Company recorded an impairment of inventories totaling $245,563. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the years ended March 31, 2021 and 2020 was $4,661 and $6,991, respectively. Impairment of Long-Lived Assets The long-lived assets held and used by the Company are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the carrying amount of any long-lived asset may be impaired, an evaluation of recoverability is performed. There were no impairment losses during the years ended March 31, 2021 and 2020. Revenue Recognition The Company 1) identifies the contract with the customer 2) identifies the performance obligations in the contract 3) determines the transaction price, 4) determines if an allocation of that transaction price is required to the performance obligations in the contract, and 5) recognizes revenue when or as the companies satisfies a performance obligation. We offer skincare products through our online store. Revenues are recognized gross when control of our goods are transferred to the customer, which generally occurs upon delivery to the customer. At the time an order is accepted, prices are fixed and determinable and are not subject to adjustment. The Company defers revenue where the earnings process is not yet complete. Share-Based Payments The Company recognizes the cost of employee share-based payment awards on a straight-line attribution basis over the requisite employee service period, net of estimated forfeitures. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise and the associated volatility. Peptide Technologies estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period of time the options are expected to be outstanding. Expected stock price volatility is based on the historical volatility of Peptide Technologies’ stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required in estimating the amount of share-based awards that will be forfeited prior to vesting. The fair value of restricted stock awards is based on the par value of Peptide Technologies’ common stock on the date of grant. Income Taxes Certain income and expense items are accounted for differently for financial reporting and income tax purposes. Deferred income tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities, applying enacted statutory income tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Basic and Diluted Income (Loss) Per Share Basic income (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed similar to basic income (loss) per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings per share is not shown for periods in which the Company incurs a loss because it would be anti-dilutive. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: · Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. · Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace. · Level 3 - Unobservable inputs which are supported by little or no market activity. The Company’s financial instruments include accounts payable and accrued compensation. The carrying value of these instruments approximate their fair value because of their short-term nature. Foreign Currency Translation and Transactions The financial statements are presented in U.S. dollars. Foreign-denominated monetary assets and liabilities are translated to their U.S. dollar equivalents using foreign exchange rates at the balance sheet date. Revenue and expenses are translated at average rates of exchange during the period. Related translation adjustments are reported as a separate component of stockholders’ equity, whereas gains or losses resulting from foreign currency transactions are included in the results of operations. Recent Accounting Pronouncements The Financial Accounting Standards Board Issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. The following are recent accounting pronouncements which may impact the Company: In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), specifying the accounting for leases, which supersedes the leases requirements in Topic 840, Leases. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. Lessees are permitted to make an accounting policy election to not recognize the asset and liability for leases with a term of twelve months or less. Lessors’ accounting is largely unchanged from the previous accounting standard. In addition, Topic 842 expands the disclosure requirements of lease arrangements. Lessees and lessors will use a modified retrospective transition approach, which includes several practical expedients. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company has adopted the provisions of the new standard, but it has not had an impact on the Company as it does not have any leases.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Accrued Liabilities	NOTE 4 – ACCRUED LIABILITIES Accrued compensation consists of the following: March 31, 2021 March 31, 2020 Salaries and benefits payable $ 212,000 $ 212,000 Payroll taxes payable 9,192 9,192 Total accrued compensation $ 221,192 $ 221,192 Other accrued liabilities consist of the following: March 31, 2021 March 31, 2020 Accrued audit fees $ 12,500 $ 16,000 Accrued interest 58,503 29,436 Total accrued liabilities $ 71,003 $ 45,436

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 5 – RELATED PARTY TRANSACTIONS The Company’s former Chief Financial Officer (“CFO”) advanced $0 and $2 to the Company during the years ended March 31, 2021 and 2020, respectively, to pay for operating expenses. The related-party advances totaled $130,992 as of March 31, 2021 and March 31, 2020. The advances are due on demand. The related party advances began to accrue interest at ten (10) percent per annum on July 1, 2019. Repayment is due no later than June 30, 2021. Interest expense was $13,099 and $9,869 during the years ended March 31, 2021, and March 31, 2020, respectively, which is included in other accrued liabilities.

Notes Payable to Shareholder

Notes Payable to Shareholder	12 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Notes Payable to Shareholder	NOTE 6 – NOTES PAYABLE TO SHAREHOLDER During the year ended March 31, 2019, a shareholder of the Company was issued a promissory note in the principal amount of $70,000. The note was unsecured and bore interest at ten (10) percent, per annum. This note was reissued on February 19, 2021 in the principal amount of $83,838 which included the original principal of $70,000 plus interest accrued as at February 19, 2021 in the amount of $13,838. Repayment of the note is due no later than February 19, 2023. During the year ended March 31, 2020, a shareholder was issued eight (8) additional promissory notes totaling $214,091. The notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due 24 months after the date of issue. During the year ended March 31, 2021, a shareholder was issued additional 23 promissory notes totaling $66,660. These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due 24 months after the date if issue. Future annual minimum principal only payments for shareholders notes are as follows: March 31 2022 2023 2024 Principal $ 150,094 $ 152,607 $ 71,570 Aggregate interest expense was $29,806 and $18,789 during the years ended March 31, 2021 and 2020, which is included in other accrued liabilities at March 31, 2021 and 2020, respectively.

Common Stock

Common Stock	12 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Common Stock	NOTE 7 – COMMON STOCK The Company has authorized the issuance of 675,000,000 shares of common stock with a par value of $0.001 per share.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8 – INCOME TAXES Income tax expense differs from the amount that would result from applying the federal income tax rate to earnings before income taxes. Reconciliations of the U.S. federal statutory rate to the actual tax rate are as follows for the years ended March 31, 2021 and 2020: 2021 2020 Federal tax benefit at statutory rate 21.0 % 21.0 % Permanent differences 0.0 % 0.0 % Temporary differences Provision for write down of inventory -14.6 % 0.0 % Accounts payable and accrued liabilities 0.2 % -2.4 % Other -0.2 % 0.0 % Change in valuation allowance -6.4 % -18.6 % Change in effective tax rate 0.0 % 0.0 % Total provision 0.0 % 0.0 % The composition of the Company’s deferred tax assets as of March 31, 2021 and 2020 is as follows: Asset (Liability) 2021 2020 Other $ 10,100 $ 11,000 Inventory allowance 51,600 — Net operating loss carryforwards 231,000 259,000 Valuation allowance (292,700 ) (270,000 ) Net deferred tax asset $ — $ — The valuation allowance increased by $22,700 and $21,000 during the years ended March 31, 2021 and March 31, 2020 respectively. The Company had a net operating loss carryforward balance of approximately $1,300,000 as of March 31, 2021. The Company’s net operating losses have expiration dates ranging from 2024 to 2040. The Company’s recognized and unrecognized deferred tax assets related to unused tax losses. A full valuation allowance has been recorded against the potential deferred tax assets associated with all the loss carryforwards as their utilization is not considered “more likely than not” at this time. The Company has recently filed its US federal income tax returns. The Company’s Federal tax filings are subject to audit since 2015. The Company does not have an ongoing IRS examination.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	NOTE 9 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS On April 15, 2019, a shareholder of the Company was issued a promissory note in the principal amount of $67,257 ($90,000 Canadian Funds). The note was unsecured and bore interest at ten (10) percent, per annum. This note was reissued on April 15, 2021 in the principal amount of $80,708 ($108,000 Canadian Funds) which included the original principal of $67,257 ($90,000 Canadian Funds) plus interest accrued as at February 19, 2021 in the amount of $13,451 ($18,000 Canadian Funds). Repayment of the note is due no later than April 15, 2023. On May 10, 2021, a shareholder was issued a promissory note in the principal amount of $1,240 ($1,500 Canadian Funds). This note is unsecured and bears interest at ten (10) percent per annum with principal and interest due 24 months after the date of issue. On June 2, 2021, a shareholder was issued a promissory note in the principal amount of $4,150 ($5,000 Canadian Funds). This note is unsecured and bears interest at ten (10) percent per annum with principal and interest due 24 months after the date of issue. On June 17, 2021, a shareholder was issued a promissory note in the principal amount of $16,155 ($20,000 Canadian Funds). This note is unsecured and bears interest at ten (10) percent per annum with principal and interest due 24 months after the date of issue.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates These financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could ultimately differ from those estimates. The most significant estimate impacted these financial statements relates to the recovery of our inventories due to the limited shelf life.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original maturities of three months or less.
Inventories	Inventories Inventories consist of purchased skincare products held for resale.. Inventories are valued at the lower of cost and net realizable value with the cost being determined on a first-in, first-out basis (FIFO) cost method. During the year ended March 31, 2021, the Company recorded an impairment of inventories totaling $245,563.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the years ended March 31, 2021 and 2020 was $4,661 and $6,991, respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The long-lived assets held and used by the Company are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the carrying amount of any long-lived asset may be impaired, an evaluation of recoverability is performed. There were no impairment losses during the years ended March 31, 2021 and 2020.
Revenue Recognition	Revenue Recognition The Company 1) identifies the contract with the customer 2) identifies the performance obligations in the contract 3) determines the transaction price, 4) determines if an allocation of that transaction price is required to the performance obligations in the contract, and 5) recognizes revenue when or as the companies satisfies a performance obligation. We offer skincare products through our online store. Revenues are recognized gross when control of our goods are transferred to the customer, which generally occurs upon delivery to the customer. At the time an order is accepted, prices are fixed and determinable and are not subject to adjustment. The Company defers revenue where the earnings process is not yet complete.
Share-Based Payments	Share-Based Payments The Company recognizes the cost of employee share-based payment awards on a straight-line attribution basis over the requisite employee service period, net of estimated forfeitures. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise and the associated volatility. Peptide Technologies estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period of time the options are expected to be outstanding. Expected stock price volatility is based on the historical volatility of Peptide Technologies’ stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required in estimating the amount of share-based awards that will be forfeited prior to vesting. The fair value of restricted stock awards is based on the par value of Peptide Technologies’ common stock on the date of grant.
Income Taxes	Income Taxes Certain income and expense items are accounted for differently for financial reporting and income tax purposes. Deferred income tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities, applying enacted statutory income tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
Basic and Diluted Income (Loss) Per Share	Basic and Diluted Income (Loss) Per Share Basic income (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed similar to basic income (loss) per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings per share is not shown for periods in which the Company incurs a loss because it would be anti-dilutive.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: · Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. · Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace. · Level 3 - Unobservable inputs which are supported by little or no market activity. The Company’s financial instruments include accounts payable and accrued compensation. The carrying value of these instruments approximate their fair value because of their short-term nature.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions The financial statements are presented in U.S. dollars. Foreign-denominated monetary assets and liabilities are translated to their U.S. dollar equivalents using foreign exchange rates at the balance sheet date. Revenue and expenses are translated at average rates of exchange during the period. Related translation adjustments are reported as a separate component of stockholders’ equity, whereas gains or losses resulting from foreign currency transactions are included in the results of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board Issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. The following are recent accounting pronouncements which may impact the Company: In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), specifying the accounting for leases, which supersedes the leases requirements in Topic 840, Leases. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. Lessees are permitted to make an accounting policy election to not recognize the asset and liability for leases with a term of twelve months or less. Lessors’ accounting is largely unchanged from the previous accounting standard. In addition, Topic 842 expands the disclosure requirements of lease arrangements. Lessees and lessors will use a modified retrospective transition approach, which includes several practical expedients. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company has adopted the provisions of the new standard, but it has not had an impact on the Company as it does not have any leases.

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	March 31, 2021 March 31, 2020 Salaries and benefits payable $ 212,000 $ 212,000 Payroll taxes payable 9,192 9,192 Total accrued compensation $ 221,192 $ 221,192
Schedule of Other Accrued Liabilities	March 31, 2021 March 31, 2020 Accrued audit fees $ 12,500 $ 16,000 Accrued interest 58,503 29,436 Total accrued liabilities $ 71,003 $ 45,436

Notes Payable to Shareholder (T

Notes Payable to Shareholder (Tables)	12 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Future Minimum Principal Payments On The Notes Payable	March 31 2022 2023 2024 Principal $ 150,094 $ 152,607 $ 71,570

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Reconciliation Of The Income Tax Provision	2021 2020 Federal tax benefit at statutory rate 21.0 % 21.0 % Permanent differences 0.0 % 0.0 % Temporary differences Provision for write down of inventory -14.6 % 0.0 % Accounts payable and accrued liabilities 0.2 % -2.4 % Other -0.2 % 0.0 % Change in valuation allowance -6.4 % -18.6 % Change in effective tax rate 0.0 % 0.0 % Total provision 0.0 % 0.0 %
Deferred Income Tax Assets And Liabilities	Asset (Liability) 2021 2020 Other $ 10,100 $ 11,000 Inventory allowance 51,600 — Net operating loss carryforwards 231,000 259,000 Valuation allowance (292,700 ) (270,000 ) Net deferred tax asset $ — $ —

Accrued Liabilities (Detail) -

Accrued Liabilities (Detail) - Schedule of Accrued Liabilities - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Payables and Accruals [Abstract]
Salaries and benefits payable	$ 212,000	$ 212,000
Payroll taxes payable	9,192	9,192
Total accrued compensation	$ 221,192	$ 221,192

Accrued Liabilities (Detail) _2

Accrued Liabilities (Detail) - Schedule of Other Accrued Liabilities - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Payables and Accruals [Abstract]
Accrued accounting fees	$ 12,500	$ 16,000
Accrued interest	58,503	29,436
Total accrued liabilities	$ 71,003	$ 45,436

Notes Payable to Shareholder (D

Notes Payable to Shareholder (Details) - Future Minimum Principal Payments On The Notes Payable - USD ($)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Minimum [Member]
Future Minimum Principal Payments	$ 71,570	$ 152,607	$ 150,094

Income Taxes (Detail) - Reconci

Income Taxes (Detail) - Reconciliation Of The Income Tax Provision	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Federal tax benefit at statutory rate	21.00%	21.00%
Permanent differences	0.00%	0.00%
Temporary differences:
Provision for write down of inventory	(1460.00%)	0.00%
Accounts payable and accrued liabilities	20.00%	(240.00%)
Other	(20.00%)	0.00%
Change in valuation allowance	(640.00%)	(1860.00%)
Change in effective tax rate	0.00%	0.00%
Total provision	0.00%	0.00%

Income Taxes (Detail) - Deferre

Income Taxes (Detail) - Deferred Income Tax Assets And Liabilities - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Other	$ 10,100	$ 11,000
Inventory allowance	51,600
Net operating loss carryforwards	231,000	259,000
Valuation allowance	(292,700)	(270,000)
Net deferred tax asset

Nature Of Operations (Details N

Nature Of Operations (Details Narrative)	12 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation	Nov. 18, 2005

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 1,739,102	$ 1,385,350
Total Stockholders' Deficit	$ 835,026	$ 481,274	$ 369,685

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Website Estimated Useful Life	3 years	3 years
Website Expenses Amortization	$ 4,661	$ 6,991
Impairment Losses

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Related party advances	$ 130,992	$ 130,992
Interest Expense	13,099	9,869
Chief Executive Officer [Member]
Related party advances	$ 0	$ 2

Notes Payable To Shareholder _2

Notes Payable To Shareholder (Details Narrative) - USD ($)	Jun. 02, 2021	May 10, 2021	Jun. 17, 2021	Apr. 15, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Note Amount	$ 4,150	$ 1,240	$ 16,155	$ 67,257
Note Interest Rate	10.00%	10.00%	10.00%	10.00%
Note Repayment Date				Apr. 15, 2023
Note Repayment Terms	due 24 months after the date of issue	due 24 months after the date of issue	due 24 months after the date of issue
Note Reissued				$ 80,708
Note Reissued Date				Apr. 15, 2021
Note Reissued Original Principal				$ 67,257
Interest Expense					$ 29,806	$ 18,789
Promissory Note 1
Note Amount							$ 70,000
Note Interest Rate							10.00%
Note Repayment Date							Feb. 19, 2021
Promissory Note 1 - Reissued [Member]
Note Repayment Date							Feb. 19, 2023
Note Reissued							$ 83,838
Note Reissued Date							Feb. 19, 2021
Note Reissued Original Principal							$ 70,000
Promissory Note 2 [Member]
Note Amount						$ 214,091
Note Interest Rate						10.00%
Note Repayment Terms						due 24 months after the date of issue
Promissory Note 3 [Member]
Note Amount					$ 66,660
Note Interest Rate					10.00%
Note Repayment Terms					due 24 months after the date of issue

Common Stock (Details Narrative

Common Stock (Details Narrative) - $ / shares	Mar. 31, 2021	Mar. 31, 2020
Equity [Abstract]
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	675,000,000	675,000,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Valuation Allowance (Increase/Decreased)	$ 22,700	$ 21,000
Net Operating Loss Carryforward	$ 1,300,000
Minimum [Member]
Net Operating Losses Expiration Dates	Mar. 31, 2024
Maximum [Member]
Net Operating Losses Expiration Dates	Mar. 31, 2040

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jun. 02, 2021	May 10, 2021	Jun. 17, 2021	Apr. 15, 2021
Subsequent Events [Abstract]
Event Date	Jun. 2, 2021	May 10, 2021	Jun. 17, 2021	Apr. 15, 2019
Note Amount	$ 4,150	$ 1,240	$ 16,155	$ 67,257
Note Interest Rate	10.00%	10.00%	10.00%	10.00%
Note Repayment Date				Apr. 15, 2023
Note Repayment Terms	due 24 months after the date of issue	due 24 months after the date of issue	due 24 months after the date of issue
Note Reissued				$ 80,708
Note Reissued Date				Apr. 15, 2021
Note Reissued Original Principal				$ 67,257
Note Accrued Interest				$ 13,451